Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities: 2009-2025

Historic Total Liabilities for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $22.0 million.

  • Gyre Therapeutics' Total Liabilities fell 17.92% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 17.92%. This contributed to the annual value of $27.0 million for FY2024, which is 29.06% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Total Liabilities of $22.0 million as of Q3 2025, which was down 5.32% from $23.2 million recorded in Q2 2025.
  • Gyre Therapeutics' Total Liabilities' 5-year high stood at $38.1 million during Q4 2023, with a 5-year trough of $1.6 million in Q3 2022.
  • In the last 3 years, Gyre Therapeutics' Total Liabilities had a median value of $25.5 million in 2025 and averaged $22.6 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Total Liabilities plummeted by 90.76% in 2022, and later skyrocketed by 315.17% in 2024.
  • Gyre Therapeutics' Total Liabilities (Quarterly) stood at $14.6 million in 2021, then declined by 13.98% to $12.5 million in 2022, then soared by 203.65% to $38.1 million in 2023, then declined by 29.06% to $27.0 million in 2024, then decreased by 17.92% to $22.0 million in 2025.
  • Its last three reported values are $22.0 million in Q3 2025, $23.2 million for Q2 2025, and $25.5 million during Q1 2025.